Rodman & Renshaw Initiates Coverage on TearLab Corp to Buy

Rodman & Renshaw Initiates Coverage on TearLab Corp(NASDAQ:TEAR). The shares have been rated Buy. The rating by Rodman & Renshaw was issued on Jul 12, 2016.

In a different note, On May 5, 2016, Feltl & Co. said it Upgrades its rating on TearLab Corp. The shares have been rated ‘Strong Buy’ by the firm.

TearLab Corp (TEAR) made into the market gainers list on Fridays trading session with the shares advancing 3.91% or 0.0293 points. Due to strong positive momentum, the stock ended at $0.7796, which is also near the day’s high of $0.7796. The stock began the session at $0.75 and the volume stood at 2,14,670 shares. The 52-week high of the shares is $3.0299 and the 52 week low is $0.58. The company has a current market capitalization of $27 M and it has 3,42,14,447 shares in outstanding.

TearLab Corp(TEAR) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $6.77M. Analysts had an estimated revenue of $6.53M. Earnings per share were $-0.21. Analysts had estimated an EPS of $-0.23.

Several Insider Transactions has been reported to the SEC. On Jun 1, 2016, Brock Wright (director) purchased 59,686 shares at $0.77 per share price.Also, On May 11, 2016, Joseph Jensen (CEO) purchased 133,332 shares at $0.00 per share price.On May 11, 2016, Wes Brazell (CFO) purchased 66,666 shares at $0.00 per share price, according to the Form-4 filing with the securities and exchange commission.

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company is engaged in commercial manufacturing of the TearLab Osmolarity System. The Company’s wholly owned subsidiary TearLab Research Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries metabolites (glucose) genes and proteins) at the point-of-care. The TearLab Osmolarity System measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System is an integrated testing system consisted of: the TearLab disposable the TearLab Pen and the TearLab Reader.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

TearLab Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on TearLab Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.